vVARDIS Holding AG 424B4final IPO prospectus

Debt defaultAccounting issueCustomer concentrationControlled company

Sells Curodont drill-free treatments for early cavities; Abivardi founders retain 86.9% of votes after the offering

Filed 2026-11-16 06:06 ET · Listing on NYSE

How this filing reads

Each score is our read of the filing's tone, not a rating. The bar runs from −1 (bad) to +1 (good). The tick marks the typical filing on Goblin, and the shaded band is where the middle half of filings score.How we read filings

  • HealthPost-IPO $184M cash covers $84.2M debt and $32.6M annualized operating cash use.
  • MomentumH1 revenue tripled to $28.6M as gross margin reached 86.4% and operating loss narrowed.
  • OutlookRepeat-buyer growth slowed from 106% to 74%, and preliminary 9M revenue growth eased to 114%–121%.
  • Debt default“a covenant waiver running through 3/14/2027”
  • Accounting issue“material weaknesses, including revenue and information-system controls, remain unremediated pending testing”
  • Customer concentration“largest customer represented 90% in H1 2026.”
  • Controlled company“controlling 86.9% of votes”

The final prospectus, filed when the IPO priced.

Executive Summary

vVARDIS sells Curodont cavity treatments to dental practices through distributors, earning revenue from product sales. It is concentrating on making drill-free treatment of early decay routine in U.S. dentistry through clinician education, repeat purchasing and better cavity detection. H1 2026 revenue more than tripled, and cheaper manufacturing narrowed operating losses, but management expects continued losses. The all-primary IPO raises $175M at a fully diluted economic valuation of $1.15B, giving buyers 15.3% economic ownership. Earning that valuation requires sustained treatment adoption beyond initial practice purchases, while substantial financing costs and founder control limit investors’ flexibility.

Business Model and Growth Drivers

Curodont Repair Fluoride Plus generates the vast majority of revenue. Its peptide technology supports mineral formation inside early, non-cavitated lesions, aiming to arrest or reverse decay before fillings become necessary. Treatment takes five minutes or less without drilling, anesthesia or specialized equipment; it is not intended for advanced decay. Since the U.S. launch in 1/2024, products had treated more than 3.5M teeth and reached more than 20,000 practices by 6/30/2026. The company cites extensive research, although evidence varies by study and some research was company-funded.

The U.S. commercial team acquires and educates practices; Henry Schein distributes products. Henry Schein represented 72% of FY2025 sales, while the largest customer represented 90% in H1 2026. Distributors have no minimum-purchase obligations, so shipments need not match patient demand.

Recurring buying practices—those ordering more than once during the preceding four months—reached 11,158 in Q3 2026. Their growth slowed from 106% in Q1 to 74% in Q3. Partnerships with VideaHealth, Pearl and Henry Schein One connect detection with treatment planning; early pilots reportedly delivered three times as many treatments, not proof of broad commercial performance.

The Offering

  • At $18.00, 9,722,223 primary shares imply $175M gross proceeds. Capitalization counts 44,358,815 Class A and 143,888,790 Class B shares after the IPO, including preferred-holder anti-dilution shares. Literally pricing every share equally implies $3.39B capitalization, 5.16% buyer ownership and 112 times FY2025 revenue. However, Class B shares have one-tenth the economic rights: the economically comparable count is 58,747,694 Class A-equivalent shares, implying $1.06B, 16.5% ownership and 35.0 times revenue.
  • Fully diluted: adding 1,591,901 remaining restricted share units, 2,516,883 warrants, 161,661 additional IPO-vesting units and up to 663,230 founder entitlement shares gives 193,181,280 shares, or 63,681,369 economic equivalents. Implied capitalization is $3.48B mechanically, or $1.15B economically; buyer stakes are 5.03% and 15.3%, respectively. This includes IPO-assumed option exercises already in capitalization, but excludes unused plan reserves.
  • Net proceeds of $154M go to the company for working capital, operating expenses and capital expenditures, with discretion for acquisitions. The 30-day option covers 1,458,333 additional primary shares.
  • Each $18.00 share is backed by $1.45 of net tangible assets after the IPO—a $16.55 gap. Existing holders paid $3.97 per share on average.
  • Goldman Sachs and J.P. Morgan lead the offering. The prospectus is dated 11/12/2026; delivery was expected on or about 11/16/2026. Listing is on the New York Stock Exchange as VVVV.
  • Substantially all existing holders face 180-day lock-ups ending 5/11/2027; founders and affiliates face 270 days. Pledge-enforcement exceptions can permit earlier sales.

Key Financial Highlights

$M except percentages. “After IPO” assumes conversions, IPO-triggered awards and net offering proceeds; operating results remain historical.

Metric FY2024 FY2025 H1 2025 H1 2026 After IPO Investor interpretation
Revenue 12.2 30.2 9.09 28.6 — U.S. flagship volume drove expansion.
Gross margin 32.0% 74.2% 51.4% 86.4% — New manufacturing sharply reduced unit costs.
Operating loss (31.0) (42.1) (24.1) (17.6) — Commercial investment outweighed annual gains; interim operating leverage improved.
Net loss (34.7) (56.4) (32.1) (27.8) — Financing costs absorbed part of the operating improvement.
Operating cash flow (23.8) (16.3) (22.8) (16.3) — FY2025 benefited from a distributor advance.
Cash 2.34 17.5 — 29.0 184 IPO proceeds strengthen liquidity.
Debt 72.9 105 — 84.2 84.2 Offering assumptions do not repay loans.
Total liabilities — 144 — 164 133 Conversion removes a preferred-related liability.
Stockholders’ equity (76.0) (105) — (119) 126 Conversion and new cash reverse the deficit.
Tangible equity (117) (150) — (161) 84.2 Excludes goodwill and other intangible assets.
  • Growth drivers: H1 U.S. revenue supplied $19.2M of the $19.5M increase, including $17.6M from flagship volume. Manufacturing cost per box fell from $88.70 to $20.30.
  • Financing burden: H1 interest expense reached $9.02M; effective term-loan rates were 24.6% and 31.8%, including financing costs.
  • Cash quality: FY2025 cash flow benefited from Henry Schein’s $15.0M advance. Product deliveries begin consuming that prepaid balance in Q3 2026 without equivalent new cash.
  • Equity bridge: accumulated losses of $256M depressed pre-IPO equity, while $58.9M of preferred capital sat outside it. Conversion moves that capital and a $31.4M derivative liability into equity; IPO proceeds supply the remaining improvement.
  • Preliminary 9M 2026: unreviewed revenue estimates imply 114%–121% growth, slower than H1, with net loss broadly unchanged despite manufacturing gains.

Governance and Control

  • Sisters Haley and Goly Abivardi are Co-CEOs and Co-Chairs, controlling 86.9% of votes and 54.9% of economic ownership after the IPO. Each share has one vote, but Class B carries one-tenth the economic participation.
  • Swiss home-country exemptions permit less-independent governance; foreign-private-issuer status also means less frequent reporting than U.S. domestic issuers.
  • IPO-triggered awards create $9.29M of nonrecurring compensation expense. The new incentive plan can expand annually, creating further dilution.
  • Founders have pledged shares against personal borrowing of ≈$128M; refinancing could expand those pledges. The company is not the borrower, but enforcement can affect public shareholders.

Risk Assessment

  • Internal controls: material weaknesses, including revenue and information-system controls, remain unremediated pending testing, increasing reporting-error risk.
  • Adoption and valuation: the economic valuation exceeds 37 times FY2025 revenue, requiring durable treatment use despite slowing repeat-buyer growth and uncertain reimbursement.
  • Distribution and supply: concentrated customers and single-provider manufacturing activities expose sales, collections and availability to counterparty failures.
  • Regulation: the U.S. flagship operates under an over-the-counter monograph without a product-specific safety or efficacy determination; reclassification could interrupt commercialization.
  • Financing: expensive secured debt, continued cash consumption and a covenant waiver running through 3/14/2027 constrain flexibility.
  • Founder dependence: both founders lead strategy and execution; losing either could disrupt commercialization or development.
  • Control and collateral: concentrated voting power limits public influence, while founder-loan enforcement can bypass ordinary lock-up protection.

What to Watch

  • Repeat usage: recurring buying practices are expanding but decelerating; sustained additions support adoption, while stalling counts suggest initial stocking rather than routine treatment.
  • Detection partnerships: pilots show higher treatment use; broader commercial results must demonstrate that better diagnosis converts into repeat orders.
  • Margins and cash: manufacturing gains have narrowed operating losses; later results should show those gains covering commercial investment rather than being absorbed by spending and financing.
  • Controls and covenants: the FY2026 audit and waiver deadline will test whether remediation and lender compliance replace temporary protections.

Longer version: the summary of each of the prospectus's 29 sections, written by an AI model from the same filing.

Was this summary useful?

The summary and scores is written by an AI model reading the filing.

Model 006 · prompt v222 · 2026-11-16 15:41:45Z

Feedback